← Back to Search

Hormone Level Management for Obesity

Waitlist Available
Led By Christine Burt Solorzano, MD
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Normal and obese (>95th BMI%) females
Weight of 24 kg or more
Must not have
Weight<24 kg
History of Cushing's syndrome or adrenal insufficiency
Screening 3 weeks
Treatment Varies
Follow Up 14 hours (1900 - 0800 hrs)
Awards & highlights


This trial is studying how hormones develop in girls as they age, specifically looking at how weight affects hormone levels.

Who is the study for?
This trial is for girls aged 7-18 who are either at a normal weight or obese (above the 95th percentile for BMI), weighing at least 24 kg, and in any stage of puberty. They should have mostly normal lab results, though some hormone imbalances due to obesity are acceptable. Girls with severe anemia, abnormal morning cortisol levels, high 17-hydroxyprogesterone levels, underweight issues, pregnancy or history of specific adrenal gland disorders cannot participate.Check my eligibility
What is being tested?
The study aims to understand the source of male and female hormones in growing girls by using Dexamethasone to suppress hormone production and Cortrosyn to stimulate it. This will help determine if overweight affects adrenal gland activity leading to higher hormone levels compared to non-overweight girls.See study design
What are the potential side effects?
Dexamethasone may cause increased appetite, weight gain, trouble sleeping or mood swings. Cortrosyn might lead to flushing or feelings of warmth. Both drugs can potentially cause allergic reactions but these side effects vary from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am a female with a BMI in the normal range or above the 95th percentile.
I weigh at least 24 kg.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I weigh less than 24 kg.
I have had Cushing's syndrome or adrenal insufficiency.
My lab results are not within the normal range for my age.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 hours (1900 - 0800 hrs)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 hours (1900 - 0800 hrs) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in progesterone concentrations from the 2100-2300 time block to the 0500-0700 time block in normal weight girls compared to overweight girls.
Secondary outcome measures
Overnight changes in male and female hormones in response to ACTH suppression
Response to ACTH stimulation in normal weight and overweight girls

Side effects data

From 2013 Phase 4 trial • 122 Patients • NCT01474915
Deep Vein Thrombosis
Cerebrospinal fluid leak
Study treatment Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dexamethasone, CortrosynExperimental Treatment2 Interventions
Dexamethasone given 1 mg PO Cortrosyn given single IV bolus 0f 0.25 mg
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Find a Location

Who is running the clinical trial?

University of California, San DiegoOTHER
1,135 Previous Clinical Trials
1,551,160 Total Patients Enrolled
University of VirginiaLead Sponsor
761 Previous Clinical Trials
1,255,954 Total Patients Enrolled
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
1,988 Previous Clinical Trials
2,683,439 Total Patients Enrolled

Media Library

Dexamethasone Clinical Trial Eligibility Overview. Trial Name: NCT01421797 — N/A
Androgen Syndrome Research Study Groups: Dexamethasone, Cortrosyn
Androgen Syndrome Clinical Trial 2023: Dexamethasone Highlights & Side Effects. Trial Name: NCT01421797 — N/A
Dexamethasone 2023 Treatment Timeline for Medical Study. Trial Name: NCT01421797 — N/A
~0 spots leftby Aug 2024